¼¼°èÀÇ ÀÇ·á¿ë ¹ÙÀÌ¿À¹Ì¸Þƽ½º ½ÃÀå
Medical Biomimetics
»óǰÄÚµå : 1787121
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 282 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,290,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,870,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ÀÇ·á¿ë ¹ÙÀÌ¿À¹Ì¸Þƽ½º ½ÃÀåÀº 2030³â±îÁö 1,024¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 695¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÀÇ·á¿ë ¹ÙÀÌ¿À¹Ì¸Þƽ½º ¼¼°è ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 6.7%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 1,024¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ½ÉÀåÇ÷°üÀº CAGR 7.2%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 362¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Á¤Çü¿Ü°ú ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 7.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 189¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR10.5%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÀÇ·á¿ë ¹ÙÀÌ¿À¹Ì¸Þƽ½º ½ÃÀåÀº 2024³â¿¡ 189¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 213¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 10.5%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 3.3%¿Í 6.5%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.4%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ÀÇ·á¿ë ¹ÙÀÌ¿À¹Ì¸Þƽ½º ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÀÚ¿¬Àº ¾î¶»°Ô Â÷¼¼´ë ÀÇ·á Çõ½Å¿¡ ¿µ°¨À» Áִ°¡?

ÀÇ·á¿ë ¹ÙÀÌ¿À¹Ì¸Þƽ½º´Â »ý¹°ÇÐ, °øÇÐ, ÀÇÇÐÀÇ °¡Àå ¸Å·ÂÀûÀÎ Á¢Á¡ Áß Çϳª·Î ºÎ»óÇϰí ÀÖÀ¸¸ç, ÷´Ü ÇコÄÉ¾î ¼Ö·ç¼ÇÀ» °³¹ßÇϱâ À§ÇØ ÀÚ¿¬ ½Ã½ºÅÛÀ» ¸ð¹æÇÏ´Â ¿ø¸®°¡ ±× ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ °³³ä¿¡´Â »ý¹°ÇÐÀû °úÁ¤, »ý¹°, ±¸Á¶¸¦ ¿¬±¸ÇÏ°í ±× ÇüÅÂ¿Í ±â´ÉÀ» ¸ð¹æÇÑ Àç·á, ÀåÄ¡, Ä¡·á¹ýÀ» ¼³°èÇÏ´Â °ÍÀÌ Æ÷ÇԵ˴ϴÙ. ÀÇ·á ºÐ¾ß¿¡¼­´Â »ýü ¸ð¹æ Çõ½ÅÀ¸·Î °íµµ·Î Á¤±³ÇÑ Àΰø º¸Á¶±â, À̽ÄÇü ÀåÄ¡, Á¶Á÷ ½ºÄ³Æúµù, ¾à¹° Àü´Þ ½Ã½ºÅÛ µîÀ» °³¹ßÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. µµ¸¶¹ì¿¡¼­ ¿µ°¨À» ¾òÀº ¼ö¼ú¿ë Á¢ÂøÁ¦ºÎÅÍ »ó¾î °¡Á×À» ¸ð¹æÇÑ Ç×±Õ Ç¥¸é, »êÈ£ ±¸Á¶¸¦ ¹Ý¿µÇÑ »À Àç»ý ¼ÒÀç¿¡ À̸£±â±îÁö »ýü ¸ð¹æÀº Çö´ë ÀǷḦ ½É¿ÀÇÑ ¹æ½ÄÀ¸·Î À籸¼ºÇϰí ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ÀÎü¿Í ¿øÈ°ÇÏ°Ô »óÈ£ÀÛ¿ëÇÏ¿© °ÅºÎ¹ÝÀÀÀÇ À§ÇèÀ» ÁÙÀ̰í Ä¡·á °á°ú¸¦ Çâ»ó½ÃŰ´Â »ýü¸ð¹æ ¼ÒÀç¿¡ ´ëÇÑ °ü½Éµµ ÁõÆøµÇ°í ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ ±ÞÁõÀÇ ÁÖ¿ä ¿øµ¿·Â Áß Çϳª´Â ½ÉÇ÷°üÁúȯ, °ñ°üÀý¿°, ÅðÇ༺°üÀý¿°, ½Å°æÀå¾Ö µî ¸¸¼ºÁúȯ ¹× ÅðÇ༺ ÁúȯÀÇ ºÎ´ãÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ±âÁ¸ÀÇ Ä¡·á Á¢±Ù¹ýÀº ÀÚ¿¬ Á¶Á÷ÀÇ °Åµ¿°ú ³»±¸¼ºÀ» ÀçÇöÇÒ ¼ö ¾ø´Â °æ¿ì°¡ ¸¹Áö¸¸, »ýü¸ð¹æ ¼Ö·ç¼ÇÀº ÀÚ¿¬ Á¶Á÷ÀÇ ±â°èÀû, Àü±âÀû, »ý¹°ÇÐÀû Ư¼ºÀ» Á¤È®ÇÏ°Ô ÀçÇöÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ¶ÇÇÑ, 3D ÇÁ¸°ÆÃ°ú ³ª³ë±â¼úÀÇ ¹ßÀüÀ¸·Î ¸ÂÃãÇü »ýü ¸ð¹æ Á¦Ç°ÀÇ ¼³°è ¹× Á¦Á¶°¡ °¡¼ÓÈ­µÇ°í ÀÖÀ¸¸ç, ÀÚ¿¬¿¡¼­ º¼ ¼ö ÀÖ´Â ¹Ì¼¼±¸Á¶¸¦ Á¤È®ÇÏ°Ô ÀçÇöÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ¿À·£ ÀÓ»ó °úÁ¦¿¡ ´ëÇÑ Çõ½ÅÀûÀÎ ÇØ°áÃ¥À» ¸ð»öÇÏ´Â °øÁߺ¸°Ç±â°ü, Çмú±â°ü, ¹Î°£ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ÀÇ ÅõÀÚ Áõ°¡¿¡ ÈûÀÔÀº ¹Ù Å®´Ï´Ù. ±× °á°ú, »ýü¸ð¹æÀº ½ÇÇèÀûÀÎ Æ´»õ ºÐ¾ß¿¡¼­ Àç»ýÀÇ·á¿Í Á¤¹ÐÀÇ·áÀÇ ÇÙ½ÉÀ¸·Î À̵¿Çϰí ÀÖ½À´Ï´Ù.

ÀÇ·á ºÐ¾ß¿¡¼­ »ýü ¸ð¹æ Çõ½ÅÀ» Çü¼ºÇÏ´Â ±â¼ú·ÂÀº ¹«¾ùÀΰ¡?

ÀÇ·á¿ë ¹ÙÀÌ¿À¹Ì¸Þƽ½º ½ÃÀåÀº ƯÈ÷ Àç·á°úÇÐ, »ýü°øÇÐ, ·Îº¿°øÇÐ µîÀÇ ºÐ¾ß¿¡¼­ ±Þ¼ÓÇÑ ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ Å©°Ô Çü¼ºµÇ°í ÀÖ½À´Ï´Ù. Á¶Á÷°øÇÐÀÇ È¹±âÀûÀÎ ¹ßÀüÀ¸·Î ¼¼Æ÷¿Ü ¸ÅÆ®¸¯½º¸¦ ¸ð¹æÇÑ ÇÕ¼º ºñ°è°¡ °³¹ßµÇ¾î Á¶Á÷ Àç»ýÀ» À§ÇÑ ¼¼Æ÷ Á¢Âø, ¼ºÀå, ºÐÈ­¸¦ Áö¿øÇϰí ÀÖ½À´Ï´Ù. ½º¸¶Æ® ¹ÙÀÌ¿À¼ÒÀç(pH, ¿Âµµ, Àü±âÀå µîÀÇ Àڱؿ¡ ¹ÝÀÀÇÏ´Â ¹ÙÀÌ¿À¼ÒÀç)´Â Á¦¾îµÈ ¹æÃâ ÇÁ·ÎÆÄÀϰú ȯÀÚÀÇ »ý¸®Àû »óÅ¿¡ µû¸¥ ÀûÀÀÀû °Åµ¿À» Á¦°øÇÔÀ¸·Î½á ¾à¹° Àü´Þ ¹× »óó Ä¡À¯¿¡ »õ·Î¿î ±æÀ» ¿­¾î°¡°í ÀÖ½À´Ï´Ù. ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º°øÇÐÀÇ Çõ½ÅÀº ¾à¹° Å×½ºÆ® ¹× Áúº´ ¸ðµ¨¸µÀ» À§ÇØ Àüü ÀÎü Àå±âÀÇ ±â´ÉÀ» ÀçÇöÇÏ´Â Àå±â ¿Â-Ĩ ¸ðµ¨À» ¼³°èÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù.

¶ÇÇÑ, ÀΰøÁö´É°ú ¸Ó½Å·¯´×Àº »ýü ¸ð¹æ ¼³°è¸¦ °¡¼ÓÈ­Çϱâ À§ÇØ Á¡Á¡ ´õ ¸¹ÀÌ È°¿ëµÇ°í ÀÖ½À´Ï´Ù. ¾Ë°í¸®ÁòÀº »ý¹°ÇÐÀû µ¥ÀÌÅ͸¦ ºÐ¼®ÇÏ¿© ÇÕ¼ºÀûÀ¸·Î ¼³°èÇÒ ¼ö ÀÖ´Â ÃÖÀûÀÇ ±¸Á¶¿Í °Åµ¿À» ÆÄ¾ÇÇÕ´Ï´Ù. ÆÈ´Ù¸®¿Í °üÀýÀÇ º¹ÀâÇÑ ¿òÁ÷ÀÓÀ» ¸ð¹æÇϱâ À§Çؼ­´Â ±â°èÀû º¹Á¦»Ó¸¸ ¾Æ´Ï¶ó ½Å°æ ÀÎÅÍÆäÀ̽ºµµ ÅëÇÕÇØ¾ß ÇÕ´Ï´Ù. ¶Ç ´Ù¸¥ Áß¿äÇÑ °¡´É¼ºÀº ºÐÀÚ ¼öÁØ¿¡¼­ ¼¼Æ÷¿Í Á¶Á÷ÀÇ Ç¥¸é°ú ±â°èÀû Ư¼ºÀ» ¸ð¹æÇÏ´Â ³ª³ë ±¸Á¶ Àç·áÀÇ »ç¿ëÀÔ´Ï´Ù. À̵éÀº Àü·Ê ¾ø´Â ƯÀ̼º°ú »ýü ÀûÇÕ¼ºÀ» °¡Áø ÷´Ü Áø´Ü, Ç¥Àû ¾à¹° Àü´Þ, ¹ÙÀÌ¿À ¼¾¼­¿¡ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀÇ À¶ÇÕÀ¸·Î Á¤Çü¿Ü°ú, ½ÉÀ庴Çп¡¼­ ¾È°ú, ÇǺΰú¿¡ À̸£±â±îÁö »ýü ¸ð¹æ ±â¼úÀÇ ÀÀ¿ë ºÐ¾ß°¡ Å©°Ô È®´ëµÇ°í ÀÖ½À´Ï´Ù.

ÇコÄÉ¾î ºÐ¾ß¿¡¼­ »ýü¸ð¹æ ±â¼úÀ» È®´ëÇÏ´Â ¼±±¸ÀÚ ¹× ½Å±Ô ÁøÃâ±â¾÷Àº?

ÀÇ·á¿ë ¹ÙÀÌ¿À¹Ì¸Þƽ½º±â¼úÀÇ Ã¤ÅÃÀº ´õ ÀÌ»ó ¼Ò¼öÀÇ Çмú ¿¬±¸¼Ò³ª Æ´»õ »ý¸í°øÇÐ ±â¾÷¿¡ ±¹ÇÑµÈ °ÍÀÌ ¾Æ´Õ´Ï´Ù. ´ëÇü ÀÇ·á ±â¼ú ±â¾÷, ´ëÇü Á¦¾à»ç, ½ÉÁö¾î ¼ÒºñÀÚ °Ç°­ ºê·£µå±îÁö ÀÌ ºÐ¾ß¿¡ ¶Ù¾îµé¾î ¸·´ëÇÑ ÅõÀÚ¿Í ±¤¹üÀ§ÇÑ »ó¾÷È­ÀÇ ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù. ÀÏ·ù ¿¬±¸ ´ëÇаú ´ÙÇÐÁ¦ ¿¬±¸±â°üÀº Çõ½ÅÀ» ÃßÁøÇÏ´Â µ¥ ÀÖ¾î ±âÃÊÀûÀÎ ¿ªÇÒÀ» °è¼ÓÇϰí ÀÖÀ¸¸ç, ÀÓ»ó Àû¿ë ¹× Á¦Ç° °³¹ßÀ» À§ÇØ ¾÷°è °ü°èÀÚµé°ú Çù·ÂÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. »ýü¸ð¹æ¼ÒÀç, Àç»ýÀÇ·á, ¼ÒÇÁÆ® ·Îº¿À» Àü¹®À¸·Î ÇÏ´Â ½ºÅ¸Æ®¾÷µéÀÌ º¥Ã³Ä³ÇÇÅаú ¾×¼¿·¯·¹ÀÌÅÍÀÇ ÁÖ¸ñÀ» ¹Þ°í ÀÖÀ¸¸ç, ÀÌ´Â ÀÌ ºÐ¾ßÀÇ »ó¾÷Àû °¡´É¼º¿¡ ´ëÇÑ ½ÃÀåÀÇ ½Å·Ú°¡ ³ô¾ÆÁ³À½À» ¹Ý¿µÇÕ´Ï´Ù.

ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üµéµµ ƯÈ÷ ¼ö¼ú°ú ÀçȰ ºÐ¾ß¿¡¼­ °ý¸ñÇÒ ¸¸ÇÑ ¼º°ú¸¦ °ÅµÎ°í ÀÖ´Â »ýü ¸ð¹æ ÁßÀ縦 ¹Þ¾ÆµéÀ̰í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, »ÀÀÇ ±â°èÀû Ư¼ºÀ» ¸ð¹æÇÑ Á¤Çü¿Ü°ú¿ë ÀÓÇöõÆ®´Â ±âÁ¸ ±Ý¼Ó ÀÓÇöõÆ®¿¡ ºñÇØ ¿ì¼öÇÑ ÅëÇÕ¼º°ú °íÀå·ü °¨¼Ò·Î ÀÎÇØ ºü¸£°Ô äÅõǰí ÀÖ½À´Ï´Ù. ½ÉÇ÷°ü°è Ä¡·á ºÐ¾ß¿¡¼­´Â Ç÷°üÀÇ ¿ªµ¿ÀûÀÎ È帧 ÆÐÅÏ¿¡ ¸Â°Ô ¼³°èµÈ »ýü°øÇÐ ±â¹ÝÀÇ ½ºÅÙÆ®³ª ½ÉÀå ÆÇ¸·ÀÌ Àå±âÀûÀÎ ³»±¸¼º°ú ȯÀÚ ÀûÇÕ¼º ¶§¹®¿¡ ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ¼Ò¾Æ ÀÇ·á ¹× ³ëÀÎ ÀÇ·á ºÐ¾ß¿¡¼­µµ ºÎµå·´°í ÀûÀÀ·Â ÀÖ°í ¸ÂÃã Ä¡·á ¼Ö·ç¼ÇÀÇ Çʿ伺À¸·Î ÀÎÇØ »ýü ¸ð¹æ ±â¼úÀÇ Àû¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÇÑÆí, ½ÅÈï °æÁ¦±¹ ¼ö¿ä Áõ°¡´Â ÀÚ¿øÀÌ ÇÑÁ¤µÈ ȯ°æ¿¡ ¸Â´Â ºñ¿ë È¿À²ÀûÀÎ »ýü ¸ð¹æ ±â¼ú °³¹ßÀ» ÃËÁøÇÏ¿© Àü ¼¼°è äÅà »óȲÀ» ´õ¿í ´Ù¾çÈ­½Ã۰í ÀÖ½À´Ï´Ù.

ÀÇ·á¿ë ¹ÙÀÌ¿À¹Ì¸Þƽ½º ½ÃÀå ¼ºÀå °¡¼ÓÈ­ÀÇ ¿øµ¿·ÂÀº?

ÀÇ·á¿ë »ýü ¸ð¹æ ½ÃÀåÀÇ ¼ºÀåÀº ¿£Áö´Ï¾î¸µ ±â¼úÀÇ ¹ßÀü, ÃÖÁ¾ »ç¿ëÀÚ ÀÀ¿ë ºÐ¾ß È®´ë, ÀÇ·á ¿ì¼± ¼øÀ§ÀÇ ÁøÈ­¿¡ ±â¹ÝÇÑ ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÀÓ»óÀÇ¿Í È¯ÀÚ ¸ðµÎ ´õ ³ªÀº ÅëÇÕ¼º, ±ä ¼ö¸í, ÃÖ¼ÒÇÑÀÇ ºÎÀÛ¿ëÀ» Á¦°øÇÏ´Â ¼Ö·ç¼ÇÀ» ¿øÇϱ⠶§¹®¿¡ »ý¹°ÇÐÀûÀ¸·Î ȣȯµÇ°í ±â´ÉÀûÀ¸·Î ¿ì¼öÇÑ ÀÇ·á±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. Á¤Çü¿Ü°ú ¼ö¼ú, ½ÉÇ÷°ü ¼ö¼ú, Ä¡°ú Ä¡·á, ƯÈ÷ °í·ÉÈ­ »çȸ Áõ°¡´Â ½Åü º»·¡ÀÇ ½Ã½ºÅÛÀ» ¸ð¹æÇÑ ÀÓÇöõÆ® ¹× º¸Ã¶¹°¿¡ ´ëÇÑ ¼ö¿ä¸¦ °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²², ÃÖ¼Òħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä´Â Ä¡À¯¸¦ °³¼±ÇÏ°í ¿Ü°úÀû ¿Ü»óÀ» °¨¼Ò½ÃŰ´Â »ýü ¸ð¹æ Á¢ÂøÁ¦, ºÀÇÕ»ç, ºñ°èÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¼ÒºñÀÚ Çൿµµ ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, ȯÀÚµéÀº ´õ ºü¸¥ ȸº¹°ú »îÀÇ Áú Çâ»óÀ» ¾à¼ÓÇÏ´Â Â÷¼¼´ë ÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ Àνİú ¼±È£µµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. º´¿ø°ú ¼ö¼ú¼¾ÅÍ´Â °æÀïÀûÀÎ ÀÇ·á ȯ°æ¿¡¼­ ¿ìÀ§¸¦ Á¡Çϱâ À§ÇØ »ýü ¸ð¹æ ±â¼ú¿¡ ÅõÀÚÇϰí ÀÖÀ¸¸ç, ȯÀÚ °á°ú °³¼±°ú Àå±âÀûÀÎ ºñ¿ë Àý°¨À» À§ÇØ »ýü ¸ð¹æ ±â¼ú¿¡ ÅõÀÚÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ±³À° Ä¿¸®Å§·³°ú ¿¬±¸ºñÀÇ Æ²¿¡ »ýü ¸ð¹æÀÌ Æ÷ÇԵǸ鼭 ÀÚ¿¬¿¡¼­ ¿µ°¨À» ¹ÞÀº Çõ½Å¿¡ ´É¼÷ÇÑ Â÷¼¼´ë ¹ÙÀÌ¿À ¸ÞµðÄà ¿£Áö´Ï¾î°¡ ¾ç¼ºµÇ°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ Ãø¸é¿¡¼­´Â »ýü¸ð¹æ Á¦Ç°¿¡ ƯȭµÈ °æ·Î°¡ Á¡Â÷ Á¤ºñµÇ°í ÀÖÀ¸¸ç, ½ÂÀÎÀÌ È¿À²È­µÇ¾î ¾÷°èÀÇ ½Å·Ú°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ½ÅÈï±¹ ½ÃÀå¿¡¼­´Â ÀÇ·á ÀÎÇÁ¶ó°¡ °³¼±µÇ°í ÀÇ·áºñ°¡ Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀ̰í ÀûÀÀ·ÂÀÌ ³ôÀº »ýü ¸ð¹æ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¹®ÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ä¼ÒµéÀÌ À¶ÇյǸ鼭 »ýü¸ð¹æÀº ´Ü¼øÇÑ °úÇÐÀû È£±â½ÉÀÌ ¾Æ´Ñ Àü ¼¼°è ÀÇ·á ÇöÀåÀÇ Çõ½Å°ú ¼ºÀåÀÇ Áß¿äÇÑ ¿øµ¿·ÂÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(½ÉÀåÇ÷°ü, Á¤Çü¿Ü°ú, ¾È°ú, Ä¡°ú, ±âŸ), ¿ëµµ(»óó Ä¡À¯, Á¶Á÷°øÇÐ, ¾à¹°Àü´Þ, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Medical Biomimetics Market to Reach US$102.4 Billion by 2030

The global market for Medical Biomimetics estimated at US$69.5 Billion in the year 2024, is expected to reach US$102.4 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Cardiovascular, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$36.2 Billion by the end of the analysis period. Growth in the Orthopedic segment is estimated at 7.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$18.9 Billion While China is Forecast to Grow at 10.5% CAGR

The Medical Biomimetics market in the U.S. is estimated at US$18.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$21.3 Billion by the year 2030 trailing a CAGR of 10.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Medical Biomimetics Market - Key Trends & Drivers Summarized

How Is Nature Inspiring the Next Generation of Medical Breakthroughs?

Medical biomimetics is emerging as one of the most fascinating intersections of biology, engineering, and medicine, driven by the principle of mimicking natural systems to develop advanced healthcare solutions. The concept involves studying biological processes, organisms, and structures to engineer materials, devices, and treatments that emulate their form or function. In the medical field, biomimetic innovations are enabling the creation of highly sophisticated prosthetics, implantable devices, tissue scaffolds, and drug delivery systems. From gecko-inspired surgical adhesives to sharkskin-mimicking antibacterial surfaces and bone-regenerating materials that mirror coral structure, biomimetics is reshaping modern healthcare in profound ways. The increasing focus on personalized medicine has also amplified interest in biomimetic materials that can interact seamlessly with the human body, reducing risks of rejection and improving therapeutic outcomes.

One of the primary drivers behind this surge is the growing burden of chronic diseases and degenerative conditions such as cardiovascular disorders, osteoarthritis, and neurological impairments. Traditional treatment approaches often fall short in replicating natural tissue behavior or durability, whereas biomimetic solutions aim to replicate the exact mechanical, electrical, and biological properties of native tissues. Moreover, advancements in 3D printing and nanotechnology have accelerated the design and fabrication of customized biomimetic products, allowing precise replication of microscopic structures found in nature. The trend is also supported by rising investments from public health agencies, academic institutions, and private biotech firms seeking innovative solutions to longstanding clinical challenges. As a result, biomimetics is transitioning from an experimental niche to a cornerstone of regenerative and precision medicine.

What Are the Technological Forces Shaping Biomimetic Innovations in Medicine?

The medical biomimetics market is being profoundly shaped by rapid technological evolution, particularly in areas like materials science, bioengineering, and robotics. Breakthroughs in tissue engineering have led to the development of synthetic scaffolds that mimic the extracellular matrix, supporting cell adhesion, growth, and differentiation for tissue regeneration applications. Smart biomaterials-those that respond to stimuli such as pH, temperature, or electric fields-are opening new avenues in drug delivery and wound healing by offering controlled release profiles and adaptive behavior in response to the patient’s physiological conditions. Innovations in microfluidics are enabling the design of organ-on-a-chip models that replicate the functions of entire human organs for drug testing and disease modeling.

Additionally, artificial intelligence and machine learning are increasingly being used to accelerate biomimetic design. Algorithms analyze biological data to identify optimal structures or behaviors that can be engineered synthetically. This is particularly valuable in biomimetic robotics and prosthetics, where mimicking the complex motion of limbs or joints requires not just mechanical replication, but also neural interface integration. Another critical enabler is the use of nanostructured materials, which mimic the surface and mechanical properties of cells and tissues at a molecular level. These are being applied in advanced diagnostics, targeted drug delivery, and biosensors with unprecedented specificity and biocompatibility. The convergence of these technologies is dramatically expanding the applications of biomimetics in fields ranging from orthopedics and cardiology to ophthalmology and dermatology.

Who Are the Pioneers and New Entrants Expanding Biomimetics in Healthcare?

The adoption of medical biomimetics is no longer confined to a handful of academic labs or niche biotech firms. Major medtech companies, pharmaceutical giants, and even consumer health brands are entering the field, bringing significant investments and broader commercialization pathways. Leading research universities and interdisciplinary institutions continue to play a foundational role in driving innovation, often collaborating with industry players for clinical translation and product development. Startups specializing in biomimetic materials, regenerative medicine, and soft robotics are gaining attention from venture capitalists and accelerators, reflecting growing market confidence in the field’s commercial potential.

Healthcare providers are also increasingly receptive to biomimetic interventions, especially in surgical and rehabilitation settings where outcomes have shown remarkable improvement. Orthopedic implants that mimic the mechanical properties of bone, for instance, are being rapidly adopted due to their superior integration and reduced failure rates compared to traditional metallic options. In the field of cardiovascular treatment, bioinspired stents and heart valves designed to match the dynamic flow patterns of blood vessels are being preferred for their long-term durability and patient compatibility. Pediatric and geriatric care segments are also witnessing increased application of biomimetics due to the need for gentle, adaptive, and personalized treatment solutions. Meanwhile, growing demand from emerging economies is spurring companies to develop cost-effective biomimetic technologies tailored to resource-limited settings, further diversifying the global adoption landscape.

What’s Driving the Accelerated Growth of the Medical Biomimetics Market?

The growth in the medical biomimetics market is driven by several factors rooted in advancements in engineering technologies, expanding end-user applications, and evolving healthcare priorities. The increasing demand for biologically compatible and functionally superior medical devices is a primary driver, as clinicians and patients alike seek solutions that offer better integration, longer lifespan, and minimal side effects. The rise in orthopedic, cardiovascular, and dental procedures-especially among aging populations-is accelerating the need for implants and prosthetics that emulate the body’s natural systems. In parallel, the demand for minimally invasive procedures is boosting the adoption of biomimetic adhesives, sutures, and scaffolds that improve healing and reduce surgical trauma.

Consumer behavior is also influencing growth, with patients showing increased awareness and preference for next-generation medical solutions that promise faster recovery and improved quality of life. Hospitals and surgical centers are investing in biomimetic technologies to stay ahead in a competitive healthcare environment, often motivated by better patient outcomes and lower long-term costs. The integration of biomimetics into educational curricula and research funding frameworks is fostering a new generation of biomedical engineers skilled in nature-inspired innovation. On the regulatory front, agencies are gradually creating dedicated pathways for biomimetic products, streamlining approval and boosting industry confidence. In developing markets, improved healthcare infrastructure and rising healthcare expenditure are opening doors for biomimetic solutions that are both effective and adaptable. Altogether, the convergence of these factors is establishing biomimetics not just as a scientific curiosity but as a critical driver of innovation and growth in the global medical landscape.

SCOPE OF STUDY:

The report analyzes the Medical Biomimetics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Cardiovascular, Orthopedic, Ophthalmology, Dental, Others); Application (Wound Healing, Tissue Engineering, Drug Delivery, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â